Trade

with

Theravance Inc
(NASDAQ: THRX)
AdChoices
17.08
-0.09
-0.52%
After Hours :
17.08
0.00
0.00%

Open

17.04

Previous Close

17.17

Volume (Avg)

624.31k (841.01k)

Day's Range

16.80-17.29

52Wk Range

15.76-40.82

Market Cap.

1.96B

Dividend Rate (Yield )

0.50 (1.46%)

Beta

1.87

Shares Outstanding

115.01M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Hold
    • Revenue

    • 4.76M

    • Net Income

    • -170.70M

    • Market Cap.

    • 1.96B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -10,060.80

    • PEG (Price/Earnings Growth) Ratio

    • 10.02

    • Beta

    • 1.87

    • Forward P/E

    • 27.55

    • Price/Sales

    • 833.33

    • Price/Book Value

    • -10.47

    • Price/Cash flow

    • -10.92

      • EBITDA

      • -153.15M

      • Return on Capital %

      • -38.02

      • Return on Equity %

      • -

      • Return on Assets %

      • -38.02

      • Book Value/Share

      • -1.63

      • Shares Outstanding

      • 115.01M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • 0.25 (8/26/2014)

      • Dividend Declaration Date

      • 8/6/2014

      Analyst Recommendation
      10/21/2014
      Hold
        • 1 Year Price Target

        • 20.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -29.30

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -27.09

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -8,574.47

            • 39.38

            • Net Profit Margin

            • -10,060.80

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 100.00

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -953.60

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 7.06

              • 2.92

              • Quick Ratio

              • 6.76

              • 2.35

              • Interest Coverage

              • -11.50

              • 38.02

              • Leverage Ratio

              • -

              • 2.21

              • Book Value/Share

              • -1.63

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -10.45

                • 217.39

                • P/E Ratio 5-Year High

                • -19.40

                • 634.30

                • P/E Ratio 5-Year Low

                • -4.34

                • 124.82

                • Price/Sales Ratio

                • 909.09

                • 9.52

                • Price/Book Value

                • -11.43

                • 8.61

                • Price/Cash Flow Ratio

                • -10.92

                • 50.51

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • 8/6/2014

                    • Ex-Dividend Date

                    • 8/26/2014

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -

                        (-)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • -38.02

                        (-30.20)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • -

                        (-)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • -

                      • 117.08k

                      • Inventory Turnover

                      • -

                      • 1.48

                      • Asset Turnover

                      • 0.00

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -168.86M
                      Operating Margin
                      -3,549.03
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -10.92
                      Ownership

                      Institutional Ownership

                      -

                      Top 10 Institutions

                      91.71%

                      Mutual Fund Ownership

                      40.78%

                      Float

                      41.05%

                      5% / Insider Ownership

                      4.09%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Oppenheimer Global Fund

                      •  

                        2,058,325

                      • 0.00

                      • 1.79

                      • VA CollegeAmerica Small Cap World

                      •  

                        1,897,000

                      • 0.00

                      • 1.65

                      • SPDR® S&P Pharmaceuticals ETF

                      •  

                        1,691,175

                      • 0.00

                      • 1.48

                      • Fidelity® Magellan® Fund

                      •  

                        1,596,400

                      • 0.00

                      • 1.39

                      • First Eagle Fund of America

                      •  

                        1,593,620

                      • 0.00

                      • 1.39

                      • Pictet-Biotech

                      •  

                        1,570,134

                      • 2.61

                      • 1.78

                      • American Funds NVIT Growth

                      •  

                        1,535,000

                      • 0.00

                      • 1.33

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • GlaxoSmithKline PLC

                      •  

                        29,785,600

                      • +88.34%

                      • 34.48

                      • Baupost Group LLC

                      •  

                        20,395,056

                      • -1.50%

                      • 18.00

                      • Fidelity Management and Research Company

                      •  

                        11,772,557

                      • +17.03%

                      • 10.39

                      • Iridian Asset Management LLC

                      •  

                        7,447,743

                      • +7.08%

                      • 6.57

                      • Capital World Investors

                      •  

                        7,290,900

                      • +0.55%

                      • 6.44

                      • Vanguard Group, Inc.

                      •  

                        4,796,783

                      • +2.76%

                      • 4.23

                      • OppenheimerFunds, Inc.

                      •  

                        3,797,186

                      • +2.34%

                      • 3.35

                      • BlackRock Fund Advisors

                      •  

                        3,635,943

                      • +57.01%

                      • 3.21

                      • AllianceBernstein LP

                      •  

                        2,895,897

                      • +21.74%

                      • 2.56

                      • Chesapeake Partners Management Co Inc

                      •  

                        2,805,837

                      • 0.00%

                      • 2.48

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      Distressed

                      Style

                      Small Value

                      Theravance Inc., was incorporated in Delaware in November 1996 under the name Advanced Medicine, Inc. and began operations in May 1997. The Company changed its name to Theravance, Inc. in April 2002.is a biopharmaceutical company wit...moreh a pipeline of internally discovered product candidates and collaborations with pharmaceutical companies. The Company is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections, and central nervous system (CNS)/pain. Its key programs include: RELVAR®/BREO® ELLIPTA® (fluticasone furoate/vilanterol, "FF/VI"), ANORO™ ELLIPTA™ (umeclidinium bromide/vilanterol, "UMEC/VI") and MABA (Bifunctional Muscarinic Antagonist-Beta2 Agonist), each partnered with Glax...moreo Group Limited (GSK), and its Long-Acting Muscarinic Antagonist program. Its drug discovery efforts are based on the principles of multivalency. Multivalency refers to the simultaneous attachment of a single molecule to multiple binding sites on one or more biological targets. When compared to monovalency, whereby a molecule attaches to only one binding site, multivalency can significantly increase a compound's potency, duration of action and/or selectivity. Multivalent compounds generally consist of several individual small molecules, at least one of which is biologically active when bound to its target, joined by linking components. The Company has limited in-house active pharmaceutical ingredient (API) production capabilities, and rely primarily on a number of third parties, including contract manufacturing organizations and collaborative partners, to produce active pharmaceutical ingredient and drug product. The development and commercialization of VIBATIV® and its product candidates and ongoing research are subject to extensive regulation by governmental authorities in the United States and other countries.lessless

                      Key People

                      Michael W. Aguiar

                      CEO/Chief Accounting Officer/Director/President

                      Rick E. Winningham

                      Chairman of the Board/Director

                      Mr. Eric d'Esparbes

                      Senior VP/CFO

                      William H. Waltrip

                      Director

                      Catherine J. Friedman

                      Director

                      • Theravance Inc

                      • 901 Gateway Boulevard

                      • South San Francisco, CA 94080

                      • USA.Map

                      • Phone: +1 650 808-6000

                      • Fax: +1 650 827-8690

                      • theravance.com

                      Incorporated

                      1996

                      Employees

                      241

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: